Safety of the anti-CD19 antibody Tafasitamab in long term responders from a phase II trial for relapsed lymphoma

Tafasitamab is a humanized Fc-modified cytolytic monoclonal antibody targeting CD19, which is expressed on most B-NHL, and is currently evaluated in relapsed or refractory lymphoma. Still little is known about its long-term effects. We evaluated long-term tolerability and toxicity in 5 patients with ongoing single-agent treatment for up to 5 years or longer, enrolled in a phase IIa trial. Responding patients could be treated until progression. Prolonged treatment was very well tolerated with only few adverse events (AEs) occurring mainly within the first 2 years, commonly infections (45%) and neurological symptoms (14%).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research